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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.009Neovascularization of the airways occurs in several inﬂammatory lung diseases, including asthma. Vascular
endothelial growth factor (VEGF) plays an important role in vascular remodeling in the asthmatic airways.
Fatty acid binding protein 4 (FABP4 or aP2) is an intracellular lipid chaperone that is induced by VEGF in
endothelial cells. FABP4 exhibits a proangiogenic function in vitro, butwhether it plays a role inmodulation of
angiogenesis in vivo is not known. We hypothesized that FABP4 promotes VEGF-induced airway angiogenesis
and investigated this hypothesis with the use of a transgenic mouse model with inducible overexpression of
VEGF165 under a CC10 promoter [VEGF-TG (transgenic) mice]. We found a signiﬁcant increase in FABP4 mRNA
levels and density of FABP4-expressing vascular endothelial cells inmouse airways with VEGF overexpression.
FABP4/ mouse airways showed a signiﬁcant decrease in neovessel formation and endothelial cell prolif-
eration in response to VEGF overexpression. These alterations in airway vasculature were accompanied by
attenuated expression of proinﬂammatory mediators. Furthermore, VEGF-TG/FABP4/ mice showed mark-
edly decreased expression of endothelial nitric oxide synthase, a well-known mediator of VEGF-induced
responses, compared with VEGF-TG mice. Finally, the density of FABP4-immunoreactive vessels in endo-
bronchial biopsy specimens was signiﬁcantly higher in patients with asthma than in control subjects. Taken
together, these data unravel FABP4 as a potential target of pathologic airway remodeling in asthma.
(Am J Pathol 2013, 182: 1425e1433; http://dx.doi.org/10.1016/j.ajpath.2012.12.009)Supportedbygrants from theAmericanHeartAssociation (11GRNT4900002
to S.C.) andBWHBiomedical Research Institute (S.C.) and in part byNIH grant
DK064360 (G.S.H.).
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and Surgeons, New York, New York.Vascular remodeling of the airways is a key feature in the
pathophysiology of asthma.1 Increased levels of vascular
endothelial growth factor A (VEGF), a key mediator of
angiogenesis, is detected in bronchoalveolar lavage ﬂuid
and in airway mucosa and correlate both with the degree of
mucosal vascularity and severity of disease in asthma.2e5
The total number of vessels and vascular area in the
lamina propria of the airway mucosa is signiﬁcantly in-
creased in patients with asthma than in control subjects.6e8
The airway hypervascularity has been proposed to perpet-
uate the airway obstruction and hyperactivity by increasing
trafﬁcking of inﬂammatory cells, exudation of mediators,
and microvascular leakage.9e11 This concept has beenstigative Pathology.
.supported by studies in a transgenic mouse model of VEGF
overexpression, which have provided a link between VEGF-
induced neovascularization and type 2 helper T cell type
inﬂammation in the lung.12 Although these studies have
Ghelﬁ et alsuggested that VEGF inhibition could have some trans-
lational potential in asthma,13 VEGF has a multitude of
effects in the lung, most of which are beneﬁcial to main-
taining the integrity of the lung structure.14,15
Fatty acid binding protein 4 (FABP4, adipocyte-FABP,
aP2), a small cytosolic lipid-binding protein with a molec-
ular weight of approximately 15 kDa, plays an important
role in regulation of glucose and lipid homeostasis as well as
inﬂammation through its actions in adipocytes and macro-
phages.16,17 Previous studies have also indicated a signiﬁ-
cant role for this protein in allergic asthma, although the
exact mechanism underlying this effect is not clear.18 In
recent studies, we have detected FABP4 expression in
a subset of endothelial cells in several tissues and identiﬁed
FABP4 as a target of the VEGF/VEGFR2 signaling
pathway.19,20 With the use of in vitro models, we demon-
strated that FABP4 plays a proangiogenic role in endothelial
cells by promoting cell proliferation, migration, survival,
and morphogenesis.21 Furthermore, we found that several
angiogenic pathways in endothelial cells are regulated by
FABP4, including stem cell factor/c-kit and endothelial
nitric oxide synthase (eNOS). Interestingly, endothelial cell
FABP4 expression is primarily detected in bronchial
circulation-derived vessels in the lung.19,22 Taking advan-
tage of this intriguing expression pattern, we have recently
demonstrated that FABP4-expressing bronchial vasculature
undergoes an expansion in bronchopulmonary dysplasia,
a common chronic lung disease of premature infants, similar
to that observed in asthma.22
Collectively, these studies have suggested that FABP4, as
a downstream target of VEGF, could play a role in the
regulation of pathologic airway angiogenesis that occurs in
several inﬂammatory lung diseases, including asthma.
Inhibition of FABP4 could have a key advantage over
VEGF blockers because of its restricted expression pattern
in the normal lung. Thus, we hypothesized that VEGF-
induced bronchial angiogenesis and inﬂammation may be
regulated by endothelial cell FABP4 in vivo. To investigate
this hypothesis, we took advantage of the VEGF-TG
(transgenic) mouse model that develops airway angiogen-
esis and inﬂammation by inducible overexpression of
VEGF165 under a Clara cell 10-kDa promoter.
12,23 We also
explored the clinical relevance by examining the expression
of FABP4 in endobronchial biopsy samples obtained from
asthmatic subjects.
Materials and Methods
Animals and Human Specimens
Dual transgenic CC10-rtTA-VEGF (VEGF-TG) mice were
generated at Yale University as previously described.12
Male VEGF-TG heterozygote mice were bred with female
FABP4/ mice (both on C57BL/6J background as previ-
ously described24) to generate the VEGF-TG/FABP4/
mouse line. Five- to six-week-old transgenic and wild-type1426(WT) or FABP4/ littermate control mice were given water
that contained 0.5 mg/mL doxycycline hydrochloride (dox-
water; Sigma Chemical Co., St. Louis, MO) and were
sacriﬁced at various intervals thereafter. Tracheas were
harvested and snap frozen or ﬁxed in 10% buffered for-
malin. The Harvard Medical Area Standing Committee on
Animals approved all animal procedures. Human samples
were obtained according to a protocol that was approved by
the Cleveland Clinic Institutional Review Board.Immunohistochemistry and Immunoﬂuorescence
Analysis
Immunohistochemistry and immunoﬂuorescence were per-
formed on formalin-ﬁxed, parafﬁn-embedded tissue sections
as previously described.22 All primary antibody incubations
were performed overnight at 4C. The primary antibodies
were used at the following concentrations: rabbit polyclonal
anti-FABP4 (Abcam, Cambridge, MA; catalog no. 13979),
1:200; rabbit monoclonal antieKi-67 (Vector Laboratories
Inc., Burlingame CA), 1:200; rat monoclonal anti-mouse
CD31 (Dianova, Germany), 1:20; and mouse monoclonal
anti-human CD31 (Dako, Carpenteria, CA), 1:50. Antigen
retrieval was performed for CD31 and Ki-67 with citrate
buffer (Vector Laboratories Inc.) at 95C for 15 minutes.
For double immunoﬂuorescence, secondary antibodies were
Alexa Fluor 594 goat anti-rat or anti-mouse IgG and Alexa
Fluor 488 goat anti-rabbit IgG (Molecular Probes Inc.,
Eugene, OR). After immunostaining of mouse sections,
slides were coded, and six to eight images per sample were
randomly selected and captured at 200 or 400 magniﬁ-
cation for quantiﬁcation of Ki-67- and CD31-expressing
cells, respectively, by a blinded investigator (E.G.). The
area between the epithelial basement membrane and the
posterior border of the cartilage plates in the tracheal
mucosa was measured with the NIS-elements BR2.30
software (Nikon, Tokyo, Japan), and the number of immu-
noreactive cells in these areas was quantiﬁed in a blinded
fashion. Human endobronchial biopsy specimens were
immunostained for FABP4, and the total number of FABP4-
immunoreactive vessels in the subepithelial area that
extended 100 mm beneath the epithelial basement membrane
was similarly quantiﬁed and normalized to the total area.Quantitative Real-Time PCR Analysis
Tracheas were homogenized, and total RNA was isolated
with TRIZOL (Invitrogen, Carlsbad, CA). First-strand
cDNA was synthesized with SuperScript First-Strand
Synthesis System for Real-Time-PCR (Invitrogen) accord-
ing to the manufacturer’s instructions. Real-time PCR
reaction was performed in a 20-mL volume with SYBR
Green (Bio-Rad, Hercules, CA) with the use of pooled
cDNA samples. The PCR primers are listed in Table 1.ajp.amjpathol.org - The American Journal of Pathology
Table 1 Real-Time PCR Primer Sequences
Gene Primer sequences
Cyclophilin A
Forward 50-TCTGAGCACTGGAGAGAAAGGA-30
Reverse 50-TATGGCGTGTAAAGTCACCACC-30
eNOS
Forward 50-ATGCCTACAGCATTGGTTGCAAGG-30
Reverse 50-AGCATATGAAGAGGGCAGCAGGAT-30
FABP4
Forward 50-TCACCATCCGGTCAGAGAGTA-30
Reverse 50-GCCATCTAGGGTTATGATGCTC-30
IL-b1
Forward 50-ACGGACCCCAAAAGATGAAG-30
Reverse 50-TTCTCCACAGCCACAATGAG-30
MCP1/CCL2
Forward 50-GTCCCTGTCATGCTTCTGG-30
Reverse 50-GCTCTCCAGCCTACTCATTG-30
SCF
Forward 50-TCAAGAGGTGTAATTGTGGACG-30
Reverse 50-GGGTAGCAAGAACAGGTAAGG-30
Figure 1 Endothelial cell FABP4 expression is induced by VEGF in the
airway mucosa. A: WT and VEGF-TG mice were given dox-water for 2 weeks
(n Z 6 per group). Tracheas were harvested and snap frozen. RNA was
isolated and reverse transcribed to ﬁrst-strand cDNA, and real-time PCR for
FABP4 was performed. Bar graph represents means  SEM values. *P <
0.05. B: VEGF-TG mice were given dox-water for 3 days (nZ 6 per group).
Tracheas were harvested, ﬁxed in 10% formalin, embedded in parafﬁn, and
immunostained for FABP4. Representative images are shown. Arrows
indicate intraepithelial capillaries with FABP4þ endothelial cells. C:
Representative images of double immunoﬂuorescence analysis for FABP4
and CD31 on mouse tracheal sections after 3 days of dox-water treatment.
Scale bars: 100 mm (B); 25 mm (C).
FABP4 in Airway AngiogenesisBone Marrow Transplantation
VEGF-TG and VEGF-TG/FABP4/ mice were irradiated
with 12 Gy in two split doses given 4 hours apart.24 WT and
FABP4/ mice of matching age were sacriﬁced on the
same day, and bone marrow was harvested from the right
tibia and femur under sterile conditions. Two hours after
irradiation, VEGF-TG and VEGF-TG/FABP4/ mice were
injected with 2  106 bone marrow cells in 150 mL of sterile
saline from FABP4/ and WT mice, respectively, via the
tail vein. The mice were administered dox-water for 3 or 7
days and euthanized 8 to 9 weeks after bone marrow
transplantation (BMT). Tracheas were harvested and pro-
cessed as described in Animals and Human Specimens.
Statistical Analysis
Results are presented as means  SEMs unless otherwise
noted. Statistical signiﬁcance was determined with Kruskal-
Wallis andU-tests for ordinal andFisherExact test for nominal
variables. P values <0.05 were considered signiﬁcant.
Results
Endothelial Cell FABP4 Expression Is Induced by VEGF
in the Mouse Airway Mucosa
To characterize the relation betweenVEGF and FABP4 in vivo,
WT andVEGF-TGmice were given dox-water for 2 weeks and
sacriﬁced. Tracheas were harvested, and mRNA was isolated
and analyzed by reverse transcription real-time PCR for FABP4
expression. RelativemRNA levels of FABP4were signiﬁcantly
increased in VEGF-TG mice than in WT mice (P < 0.05)
(Figure 1A). The localization of FABP4 on tracheal sections
was determined by immunohistochemistry in mice given dox-
water for 3 days (Figure 1B). In control WT mouse tracheas,The American Journal of Pathology - ajp.amjpathol.orgFABP4 immunoreactivity was observed in endothelial cells of
capillaries and small blood vessels in the lamina propria. In
VEGF-TG mouse tracheas, FABP4-immunoreactive endothe-
lial cellswere detected in the same locationbutwere increased in
number. Furthermore, some FABP4þ capillaries had expanded
to reach an intraepithelial location as previously reported.23
Double-immunoﬂuorescence for CD31, a pan-endothelial cell
marker, and FABP4 conﬁrmed the endothelial cell localization1427
Figure 2 FABP4 deﬁciency attenuates VEGF-induced angiogenesis in
mouse airways. A: Mice were given dox-water for 3 days. Tracheas were
harvested, ﬁxed in 10% formalin, and embedded in parafﬁn. Immunoﬂu-
orescence analysis was performed for CD31. Representative images are
shown. Scale bar Z 25 mm. B: CD31þ endothelial cells localized between
the airway lumen and posterior border of the cartilage plates were counted
and normalized to the area described. Bar graph represents means  SEM
values from 5 to 7 mice per group. *P < 0.05, **P < 0.01.
Ghelﬁ et alof FABP4 in mouse tracheal sections (Figure 1C). FABP4 was
colocalized with CD31 in most but not all of the CD31þ
endothelial cells.
FABP4-Knockout Mice Exhibit Attenuated Airway
Angiogenesis in Response to VEGF
To determine whether FABP4 plays a role in VEGF-
induced airway angiogenesis, VEGF-TG and FABP4/
mouse lines were crossed. VEGF-TG and VEGF-TG/
FABP4/ mice and their WT and FABP4/ littermates
were given dox-water for 3 days, based on pilot experiments
that showed an obvious increase in vascular density, which
was most amenable to quantiﬁcation, at this time point.
Tracheas were harvested, and immunoﬂuorescence analysis
for CD31 was performed on formalin-ﬁxed, parafﬁn-
embedded sections (Figure 2A). Quantiﬁcation of CD31þ
cells did not show any differences between WT and
FABP4/ mice, whereas the number of CD31þcells was
signiﬁcantly higher in the VEGF-TG group than in the WT
group as expected (P < 0.01) (Figure 2B). Although the
number of CD31þ cells was higher in the VEGF-TG/
FABP4/ group than in the WT or FABP4/ groups, they
were approximately 50% lower than in the VEGF-TG mice
(P < 0.05). Thus, FABP4 deﬁciency signiﬁcantly attenuated
VEGF-induced airway angiogenesis in mice.
FABP4-Knockout Mice Show Decreased Cell
Proliferation in Response to VEGF
To determine whether VEGF-induced endothelial cell pro-
liferation is regulated by FABP4, immunohistochemical
analysis for the proliferation marker Ki-67 was performed on
mouse tracheal sections (Figure 3A). The number of Ki-67þ
cells was similar in WT and FABP4/ groups and, as ex-
pected, was signiﬁcantly higher in the VEGF-TG mice than
in these two groups (P < 0.01) (Figure 3B). In accordance
with the CD31 data, a signiﬁcantly lower number of Ki-67þ
cells was detected in the VEGF-TG/FABP4/ mice than in
the VEGF-TGmice (P< 0.01). Double immunoﬂuorescence
for Ki-67 and CD31 showed that most Ki-67þ cells were
colocalized with CD31 and, thus, were endothelial cells
(Figure 3C).
FABP4-Knockout Mice Exhibit Attenuated Airway
Inﬂammation in Response to VEGF
To determine whether FABP4 had an effect on VEGF-
induced airway inﬂammation, we analyzed the mRNA
expression levels of two key proinﬂammatory mediators,
monocyte chemeotactic protein (MCP)-1 and IL-1b, in the
trachea by real-time PCR (Figure 4). Relative MCP-1
mRNA level was signiﬁcantly reduced in FABP4/
mouse tracheas than in WT samples (P < 0.01) (Figure 4A).
MCP-1 mRNA levels was also signiﬁcantly decreased in the
VEGF-TG/FABP4/ mice than in the VEGF-TG samples1428(P< 0.01). Similarly, the mRNA levels of IL-1b, another key
proinﬂammatory mediator released by activated macrophages,
was signiﬁcantly reduced in theVEGF-TG/FABP4/ tracheas
than in the VEGF-TG samples (Figure 4B).
FABP4 Deﬁciency Is Associated With Decreased Tissue
mRNA Levels of SCF and eNOS
In previous in vitro studies, we have identiﬁed stem cell
factor (SCF) as a key mediator of decreased angiogenic
function in cultured FABP4-deﬁcient endothelial cells and
FABP4/ aortic explants.21 To determine whether SCF
played a role in the attenuated angiogenic response in VEGF-
TG/FABP4/ mice, we analyzed SCF mRNA levels in
mouse tracheas after 14 days of dox-water administration
(Figure 5A). Consistent with our in vitro data, SCF mRNAajp.amjpathol.org - The American Journal of Pathology
Figure 3 FABP4 deﬁciency impairs cell prolifer-
ation in VEGF-TG mouse airways. A: WT, FABP4/,
VEGF-TG, and VEGF-TG/FABP4/ mice were given
dox-water for 3 days. Tracheas were harvested, ﬁxed
in 10% formalin, embedded in parafﬁn, and immu-
nostained for the proliferation marker Ki-67. Repre-
sentative images are shown. B: Ki-67þ cell nuclei
localized between the airway lumen and posterior
border of the cartilage plates were counted and
normalized to the area described. Bar graph repre-
sents means SEM values from 5 to 6mice per group.
**P < 0.01. C: Representative images of double
immunoﬂuorescence for CD31 and Ki-67 are shown.
Arrows indicate colocalization of CD31 and Ki-67 in
endothelial cells. Scale bars: 25 mm (B and C).
FABP4 in Airway Angiogenesislevels were decreased by approximately 50% in VEGF-TG/
FABP4/ tracheas than in VEGF-TG samples (P < 0.05).
Similar to our ﬁndings in human umbilical vein endothelial
cells, VEGF induced SCF expression in vivo, but this
difference did not reach a statistical signiﬁcance. We have
previously reported that the expression of eNOS, which is
a critical mediator of VEGF-induced pulmonary responses,
including angiogenesis, is also regulated by FABP4 in
human umbilical vein endothelial cells.21,25,26 To determine
whether eNOS was regulated by FABP4 in vivo, we exam-
ined eNOS mRNA levels in VEGF-TG mouse tracheas after
14 days of dox-water treatment. As previously reported,
eNOS levels were signiﬁcantly induced in VEGF-TG mice
than in WT mice.25 No differences were observed in eNOS
mRNA levels between WT and FABP4/ mice. VEGF
induced eNOS mRNA levels as expected (P < 0.05), and
VEGF-TG/FABP4/ mice showed signiﬁcantly decreased
levels of eNOS than did VEGF-TG mice (P < 0.01)
(Figure 5B). Thus, these in vivo data support our previous
in vitro ﬁndings and suggest that FABP4 modulates VEGF-
induced responses in murine airways, at least in part, via
regulation of SCF and eNOS pathways.
Endothelial Cell FABP4 Regulates VEGF-Mediated
Airway Angiogenesis
In addition to endothelial cells, FABP4 is expressed in
macrophages,27,28 which have the capacity to modulate
angiogenic responses.29,30 To determine the contribution of
macrophages or other bone marrow-derived cells to the
attenuated neovascularization and airway inﬂammation in
FABP4/ mice, chimeric mice were generated by BMTs.
VEGF-TG and VEGF-TG/FABP4/ mice were lethally
irradiated and reconstituted with FABP4/ or WT bone
marrow, respectively. The mice were allowed to recover forThe American Journal of Pathology - ajp.amjpathol.org8 weeks and then were given dox-water to induce VEGF
expression. The absolute numbers of CD31 and Ki-67þ
cells in the chimeric mice were lower than in the mice that
did not receive BMT, likely because of their older age at the
time of VEGF induction. However, similar differences to
those observed in the VEGF-TG versus VEGF-TG/FABP4/
mice persisted in the chimeric mice. Thus, VEGF-TG mice
reconstituted with FABP4/ hematopoietic cells (VEGF-
TGch) had signiﬁcantly higher number of CD31þ endothelial
cells (P < 0.05) and Ki-67þ cells (P < 0.01) than VEGF-TG/
FABP4/ mice reconstituted with WT hematopoietic cells
(VEGF-TG/FABP4/ch) (Figure 6, A and B, and
Supplemental Figure S1). These results indicate that lack of
FABP4 in resident endothelial cells is responsible for the
attenuated neovascular responses to VEGF in FABP4/mice.FABP4þ Vessel Density Is Increased in the Asthmatic
Airways
We analyzed FABP4 expression in endobronchial biopsy
samples obtained from patients with asthma and control
subjects. Patient characteristics are shown in Table 2. In
control specimens, FABP4 immunoreactivity was detected
in rare vascular endothelial cells in the lamina propria
(Figure 7A). In asthma samples, several blood vessels in the
lamina propria harbored FABP4þendothelial cells.
Although most airway epithelial cells were denuded in
asthma samples, some were noted to have faint diffuse
FABP4 immunoreactivity. Quantiﬁcation of FABP4þ blood
vessels showed that they were signiﬁcantly increased in
asthma samples compared with controls (P < 0.05)
(Figure 7B). Double immunoﬂuorescence for FABP4 and
CD31 in asthma samples showed colocalization of FABP4
and CD31 in some vascular endothelial cells, most of which1429
Figure 4 FABP4 deﬁciency ameliorates VEGF-induced airway inﬂam-
mation. WT, FABP4/, VEGF-TG, and VEGF-TG/FABP4/ mice were given
dox-water for 14 days (nZ 6 per group). Total RNA was isolated, and real-
time PCR was performed to determine the relative steady-state mRNA
expression levels of the proinﬂammatory cytokines MCP1 (A) and IL-1b (B).
Bar graphs represent means  SEM values. *P < 0.05, **P < 0.01.
Figure 5 FABP4 regulates SCF and eNOS expression in mouse airways.
WT, FABP4/, VEGF-TG, and VEGF-TG/FABP4/ mice were given dox-water
for 14 days (nZ 6 per group). Tracheas were harvested, and total RNA was
isolated. Real-time PCR was performed to determine the relative steady-
state mRNA expression levels of SCF and eNOS. Bar graphs represent
means  SEM values. *P < 0.05, **P < 0.01.
Ghelﬁ et alwere in closer proximity to the airway epithelium than the
ones that only expressed CD31 (Figure 7C).
Discussion
The ﬁndings of this study demonstrate that FABP4 deﬁciency
signiﬁcantly attenuates VEGF-induced airway angiogenesis
and inﬂammation in mice. Through generation of chimeric
mouse models, we showed that endothelial cell FABP4 is
responsible for modulating VEGF-induced responses in the
murine trachea. Furthermore, we found an increased density
of FABP4-immunoreactive blood vessels in the asthmatic
airways, thus providing evidence for the clinical relevance
and translational potential of our ﬁndings.
In a recent study, FABP4/ mice were found to have
attenuated airway inﬂammationwith decreased eosinophils in1430the ovalbumin-induced model of asthma.18 In that study,
generation of chimeric mice conﬁrmed that nonhematopoietic
cells, most likely airway epithelial cells, regulated allergic
lung inﬂammation in FABP4/ mice. The ovalbumin-
induced murine model of asthma was not suitable for the
purposes of our study because ovalbumin administration does
not induce airway angiogenesis in mice (E.G. and S.C.,
unpublished observations). Therefore, we used theVEGF-TG
mouse model, which exhibits both airway angiogenesis and
type 2 helper T cell type inﬂammation. Because mouse lungs
do not have a functional bronchial circulation below the level
of the main stem bronchus31,32 and FABP4 is primarily
expressed in the bronchial/systemic vasculature-derived
endothelial cells,22 we focused our histologic analysis to theajp.amjpathol.org - The American Journal of Pathology
Figure 6 Endothelial-cell FABP4 regulates VEGF-induced airway
angiogenesis. VEGF-TG and VEGF-TG/FABP4/ mice were lethally irradiated
and reconstituted with FABP4/ (VEGF-TGch) or WT bone marrow (VEGF-TG/
FABP4/ch), respectively. The mice were allowed to recover for 8 weeks
and then were given dox-water for 3 days. The number of CD31þ (A) and Ki-
67þ (B) cells were quantiﬁed. Bar graphs represent means  SEM values
from 6 mice per group. *P < 0.05, **P < 0.01.
FABP4 in Airway Angiogenesislevel of the trachea, where angiogenesis was previously
characterized in detail in this model.23 Our ﬁndings showed
that the lack of FABP4 confers protection against VEGF-
induced pathologic angiogenesis as well as airway inﬂam-
mation. Previous studies have shown decreased inﬂammatory
activity in association with decreased NF-kB and enhancedTable 2 Patient Characteristics
Patient characteristics
Control
(n Z 5)
Asthma
(n Z 6) P value
Age, means  SD (years) 33.6  6.4 37.4  10.7
Sex, N/n 3/2 2/4
FEV1, means  SD (%) 94.3  10.8 76.3  17.4 0.05
FVC, means  SD (%) 100.1  11.2 93.0  18.1
FEV1/FEC, means  SD 0.80  0.06 0.68  0.06 <0.05
Exhaled NO, means  SD
(ppb)
17.6  7.0 39.7  32.1 0.05
FEV1, forced expiratory volume 1 second; FVC, forced vital capacity; NO,
nitric oxide.
The American Journal of Pathology - ajp.amjpathol.orgperoxisome proliferator-activated receptor-g activity in
FABP4-deﬁcient macrophages.33 Because inﬂammation and
angiogenesis are closely linked processes34 and macrophages
can contribute to neovascularization,30 we examined the
possibility that lack of macrophage FABP4 could have
contributed to the observed phenotype in the VEGF-TG/Figure 7 FABP4þ vessel number is increased in humanasthmatic airways.
A: FABP4 immunohistochemistry was performed on endobronchial biopsy
specimens from healthy control subjects and patients with asthma. A
representative case from each group is shown. Black arrows indicate
FABP4þvessels. B: The total number of FABP4þvessels in the subepithelial
area extending 100 mm beneath the epithelial basement membrane was
quantiﬁed and normalized to the total area (nZ 5 to 6 per group). Bar graph
represents means  SEM values. *P < 0.05. C: Representative images of
double immunoﬂuorescence analysis for FABP4 andCD31onanendobronchial
biopsy specimen from a patient with asthma. White arrows indicate endo-
thelial cells, where FABP4 is coexpressed with CD31, whereas orange arrows
mark endothelial cells that only express CD31. Scale bars: 25 mm (A and C).
1431
Ghelﬁ et alFABP4/mice. Interestingly, our ﬁndings in chimeric mice
show that macrophage FABP4 does not play a role in regu-
lation of VEGF-induced airway angiogenesis. In previous
studies, we have found decreased expression of endothelial
cell activation markers, such as E-selectin and intercellular
adhesion molecule 1, in FABP4-deﬁcient endothelial cells.21
Taken together, our ﬁndings suggest that endothelial cell
FABP4 may have a novel role in coordinated regulation of
endothelial cell activation and angiogenesis. Regulation of
eNOS by FABP4 appears to be a potential mechanism that
could account for some of these effects because VEGF-
induced neovascularization as well as airway inﬂammation
are, at least in part, eNOS dependent.25 Another potential
mechanism for the attenuated airway inﬂammation in VEGF-
TG/FABP4/ mice may be a decrease in trafﬁcking of
inﬂammatory cells and mediators because of decreased
number of neovessels.
Although our ﬁndings are most relevant for asthma-related
vascular remodeling in the airways, they also provide some
general insights into the potential role of FABP4 in expan-
sion of bronchial circulation in other diseases, such as
bronchopulmonary dysplasia22 and idiopathic pulmonary
hypertension.35 The lung has a dual circulation through
pulmonary and bronchial vasculatures.36 Bronchial vascu-
lature, which arises from the systemic circulation, provides
blood supply to the areas around large airways, visceral
pleura, and vasa vasorum. Several lines of evidence from
animal studies as well as humans have suggested that the
bronchial vasculature has a higher angiogenic capacity than
the pulmonary vasculature.32,37 However, the underlying
causes for the differential angiogenic responses of these two
vascular beds remains largely unknown. The ﬁndings of our
study strongly suggest that FABP4 may be a key mediator
that renders a pro-angiogenic and pro-inﬂammatory pheno-
type to the bronchial/systemic endothelium.
FABP4/ mice are viable, fertile, and do not show any
developmental phenotypes.38 Thus, FABP4 does not appear
to interfere with VEGF-mediated vasculogenesis or angio-
genesis in the embryo, but rather to selectively regulate
postnatal angiogenesis, a phenomenon that has been noted
also for other effector molecules, such as Notch 1.39
However, we cannot exclude the possibility of compensa-
tion by other members of the FABP family, particularly
endothelial FABP5, in FABP4/ embryos.
In endobronchial biopsy specimens from patients with
asthma, we observed several vessels with CD31þendothelial
cells that lacked FABP4 expression. Furthermore, FABP4þ
vessels were noted to have a closer location to the bronchial
epithelium than the FABP4 vessels. These observations
support the notion that endothelial cell FABP4 is primarily
expressed in vessels undergoing remodeling and/or angio-
genesis and may serve as a more reliable marker of airway
neovascularization than a pan-endothelial cell marker, such
as CD31.
In conclusion, our ﬁndings establish a novel role for
endothelial cell FABP4 in promotion of VEGF-induced1432airway angiogenesis and inﬂammation in vivo and, in
conjunction with previous studies,18 suggest that FABP4
inhibition should be explored further as a potential thera-
peutic strategy in asthma because it appears to target at least
two diverse pathologic processes that involve airway
epithelial and endothelial cells in this disease.
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